Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

MONASHEE INVESTMENT

Investor type Hedge Fund
Founders Gerald Coughlan Tom Wynn

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 27
Average round size
info
The average size of a deal this fund participated in
$139M
Portfolio companies 27
Lead investments 1
Exits 9
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Agave Capital Cedar Park, Texas, United States
Cathay Integrity Holding Limited -
CIBER Colorado, Greenwood Village, United States
Code Investing England, London, United Kingdom
Crealize Essen, Germany, Nordrhein-Westfalen
EIT Urban Mobility Barcelona, Catalonia, Spain
Emergent Holdings Lansing, Michigan, United States
Flamingo DAO California, Sacramento, United States
Foundation for Technological Innovation -
Gogin Capital Japan, Matsue, Shimane Prefecture
Good Soil VC England, London, United Kingdom
Jobcloud SA Switzerland, Zürich, Zurich
KinderCare Education Oregon, Portland, United States
Low Carbon Seed Fund -
Majgaard Limited -
McGovern Family Trust -
Michigan Emerging Technology Fund Lansing, Michigan, United States
Ocean Solutions Accelerator California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Gossamer Bio

Biotechnology
Health Care
Therapeutics
$120M13 Jul 2022 San Diego, California, United States

MoonLake Immunotherapeutics

$115M06 Apr 2022 Zug, Zug, Switzerland

Scipher Medicine

Alternative Medicine
Artificial Intelligence
Biotechnology
Health Care
Health Diagnostics
$110M24 Feb 2022 Massachusetts, United States

AN2 Therapeutics

Biotechnology
Health Care
Pharmaceutical
$80M07 Jan 2022 California, United States

Korro Bio

Biotechnology
Pharmaceutical
$116M05 Jan 2022 Cambridge, Massachusetts, United States

Pardes Biosciences

Biotechnology
Life Science
$75M27 Dec 2021 Carlsbad, California, United States

HotSpot Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
Therapeutics
$100M29 Nov 2021 Cambridge, Massachusetts, United States

Better Therapeutics

Artificial Intelligence
Biotechnology
Health Care
Information Technology
Therapeutics
$70M29 Oct 2021 San Francisco, California, United States

Skyryse

Aerospace
Air Transportation
Internet
Transportation
$200M27 Oct 2021 California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MONASHEE INVESTMENT?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: